Pharmaceutical giants Pfizer, based in the US, and AstraZeneca, based in the UK, are now rumored to be in merger discussions, potentially striking a deal some say could be worth $101 billion.
UK reports say Pfizer has resisted the acquisition approaches from its US competitor, with which it has worked on a number of joint ventures in recent years.
While the UK pharmaceutical firm has rejected the alleged takeover approach, Pfizer could re-bid on the company in efforts to boost its cancer treatment portfolio through AstraZeneca patents.
Both companies declined to comment on the rumors, but industry experts expect the takeover discussions to be genuine.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Kenya’s Competition Authority Proposes Tougher Regulations on Big Tech
May 30, 2024 by
CPI
KKR Secures EU Antitrust Approval for $24 Billion Acquisition of Telecom Italia’s Fixed-Line Network
May 30, 2024 by
CPI
European Court Sides with Tech Giants in Italian Regulatory Dispute
May 30, 2024 by
CPI
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
EU Watchdog Mandates Boardroom Accountability for AI in Banks
May 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI